JPRN-UMIN000008529招募中1 期
PhaseI/ II study of disulfiram in patients with advanced hepatocellular carcinoma - Phase I/II study of disulfiram in patients with advanced hepatocellular carcinoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Massive pleural or abdominal effusion 2)Uncontrolled hypertension 3)Uncontrolled heart disease 4)Evidence of Myocardial infarction witin 6 months 5)Active infection (except viral hepatitis) 6)Active gastrointestinal bleeding or ulcer 7)active double cancer 8)encephalopacy or severe mental disorder 9)severe drug allergy 10)pregnancy or lactaing females 11)inadequate for administration orally 12)Inadequate physical condition,as diagnosed by primary physician
研究者
相似试验
已完成
不适用
Phase 1 study of sulfapyridine in patients with advanced gastric cancer.JPRN-UMIN000010254ational Cancer Center Hospital East6
进行中（未招募）
1 期
Study to evaluate effectiveness of disulfiram and cisplatin in patients with refractory testicular cancer.platina refractory testicular germ cell cancerMedDRA version: 20.0 Level: PT Classification code 10061184 Term: Germ cell cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-000558-68-SKárodný onkologický ústav20
进行中（未招募）
1 期
DIsulfiram REsponse as add-on to ChemoTherapy in recurrent Glioblastoma: A randomized controlled trialGlioblastomaEUCTR2016-000167-16-SESahlgrenska University Hospital142
进行中（未招募）
1 期
DIsulfiram REsponse as add-on to ChemoTherapy in recurrent Glioblastoma: A randomized controlled trialMedDRA version: 19.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)GlioblastomaEUCTR2016-000167-16-NOSahlgrenska University Hospital142
已完成
1 期
An Exploratory Study of ADR-001 in Patients with Severe Pneumonia caused by SARS-CoV-2 infection (COVID-19)Patients with Severe Pneumonia caused by SARS-CoV-2 infectionJPRN-jRCT1080225320ROHTO PHARMACEUTICAL CO., LTD.6